PD-1/PD-L1 and CTLA-4 inhibitors have been approved by the FDA and have achieved favorable efficacy in non-small cell lung cancer (NSCLC), melanoma and renal cell carcinoma (RCC) [27–30]. This evidence concerns the gene CTLA4 and renal cell carcinoma.